Shares of Hims & Hers Health, the telehealth provider that has found a niche in the obesity-drug boom, surged 28% on Thursday ...

The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

Hims & Hers has shown impressive revenue growth, accelerating from 46% to 77%. Read why I downgrade HIMS stock from buy to ...

The goal is to either have the put expire worthless and keep the premium, or be assigned and acquire the stock below the ...

Two U.S. senators wrote a letter to the Food and Drug Administration on Friday expressing concerns about an upcoming Super ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

Hims & Hers makes its Super Bowl commercial debut in 2025 with a spot for the telehealth company's weight loss medications.

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

During the Super Bowl, Hims & Hers Health aired a commercial called “Sick of the System.” But before the 60-second spot was ...

During the Super Bowl, Hims & Hers Health aired a commercial called “Sick of the System.” But before the 60-second spot was ...

Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Telehealth provider Hims & Hers Health is defending its planned Super Bowl ad, which is styled as a political manifesto ...